Abstract:Title. Androgen Receptor Protein Degraders Patent Publication Number. WO 2020/142228 A1 Publication Date. July 09, 2020 Priority Application. US 62/788,005 Priority Date. January 03, 2019 Inventors.Wang, S.; Han, X.; Wang, C.; Qin, C.; Xiang, W.; Xu, T.; Yang, C. Assignee Company. The Regents of the University of Michigan [US/US]; Office of Technology Transfer, 1600 Huron Parkway, second Floor, Ann Arbor, MI 48109−2590 (US). Disease Area. Prostate cancer (PCa) Biological Target. Androgen receptor Summary. Androgens are a class of steroid hormones that consist of natural or synthetic steroid hormone derivatives of cholesterol, which play a role in the development and maintenance of male characteristics. They function primarily through androgen receptor (AR) signaling and are recognized as a key driver of prostate cancer (PCa) growth and survival. The AR is a 110 kDa protein with sequence homology that is shared with other nuclear hormone receptors in the superfamily such as the progesterone receptor (PR), estrogen receptor (ER), and glucocorticoid receptor (GR). Furthermore, the AR consists of four basic elements: the N-terminal domain, DNA binding domain, hinge region, and ligand binding domain (LBD). The centrally located DNA binding domain consists of two zinc finger domains that recognize a specific DNA sequence and is the most highly conserved region. Whereas, the LBD forms the ligand-binding pocket that contains ligand-dependent activation function 2 (AF-2) and mediates interactions between the AR, heat shock proteins, and motifs located within the N-terminal domain. PCa remains themost common cancer and the second leading cause of cancer-related deaths inmen. However, if detected early the current arsenal of therapeutic options provide a promising chance for long-term survival, though ∼40% of patients will develop castration-resistant PCa. Androgen deprivation therapy (ADT) remains the primary treatment regimen for patients who demonstrate biochemical relapse and those that are challenged with locally advanced or metastatic disease. In some cases, the disease ultimately progresses to a lethal form despite castrating levels of testosterone and is termed metastatic castrationresistant prostate cancer (mCRPC). Most often, mCRPC is characterized by rising serum levels of prostate-specific antigen (PSA) after the restoration of the AR transcriptional activity. Consequently, the standard of care for patients with mCRPC after ADT treatment involves sustained AR inhibition that competitively bind the ligand-binding domain (LBD) of the AR or CYP17A1 inhibitors. Mutation in the AR LBD as well as active AR-splice variants that lack the LBD have been associated with primary and acquired resistance. Consequently, a new therapeutic approach is needed in the treatment of PCa and related diseases associated with the AR. The present Patent Highlight showcases heterobifunctional small molecules that are androgen receptor (AR) protein degraders useful for the treatment of a variety of diseases including prostate cancer. The Proteolysis Targeting Chimera (PROTAC) strategy consists of a heterobifunctional small molecule containing one ligand that binds to the target protein of interest (AR) and a second ligand for an E3 ligase system, tethered together by a chemical linker. Thus, AR degraders designed based upon the PROTAC concept may be effective for the treatment of CRPC when the disease becomes resistant to AR antagonists or to androgen synthesis inhibitors.

Catalytic Cleavage of the Androgen Receptor Messenger Rna and Functional Inhibition of Androgen Receptor Activity by A Hammerhead Ribozyme

Cleavage of Short Fragment of Androgen Receptor Mrna by Hammerhead Ribozyme in Vitro

The Hammerhead Ribozyme-Induced Blocking Effects on Gene Expression of Androgen Receptor

Regulation of Androgen Action by Receptor Gene Inhibition.

Ribozyme-Mediated Cleavage of the Estrogen Receptor Messenger Rna and Inhibition of Receptor Function in Target Cells

Abstract 1960: Targeted Androgen Receptor (AR) Protein Degradation for the Treatment of Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Abstract 1483: RNA interference seed-based approach to inhibit androgen signaling and induce prostate cancer cell death

Chimeric Molecules Facilitate the Degradation of Androgen Receptors and Repress the Growth of LNCaP Cells.

Androgen Receptor Protein Degradation in the Treatment of Castration-Resistant Prostate Cancer.

Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer

The Design, Synthesis and Bioactivity Evaluation of Novel Androgen Receptor Degraders Based on Hydrophobic Tagging

Abstract LB133: An orally bioavailable degrader targeting androgen receptor and the splice variant in castration resistant prostate cancer

Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening

[Targeted Degradation of Androgen Receptors in Androgen-Independent Prostate Cancer Cells: an Experimental Study].

Discovery of ARD-69 As a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.

Targeted Degradation of Androgen Receptor by VNPP433-3β in Castration-Resistant Prostate Cancer Cells Implicates Interaction with E3 Ligase MDM2 Resulting in Ubiquitin-Proteasomal Degradation

A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

Raddeanin A Down-Regulates Androgen Receptor and Its Splice Variants in Prostate Cancer

Integrated Expression Profiling And Chip-Seq Analyses Of The Growth Inhibition Response Program Of The Androgen Receptor

Abstract 6071: Identification of a molecular glue degrader targeting the full-length AR and AR-V7 splice variant